dm+d

Unassigned

New Medicines

Moderate-to-severe ulcerative colitis

Information

New molecular entity
Takeda
Takeda

Development and Regulatory status

Discontinued
Discontinued
Discontinued
May 20SHP647 will be culled from pipeline. Clinical trials will be discontinued in due course. European Commission demanded Takeda divest of this medicine when they took over Shire, in order to maintain competitive market. No purchasers for drug have been found, so it has been dropped by Takeda [5].

Category

A fully human IgG2 monoclonal antibody that targets mucosal addressin cell adhesion molecule (MADCAM1)
Ulcerative colitis is the most common type of inflammatory disease of the bowel. It has an incidence in the UK of approximately 10 per 100,000 people annually and a prevalence of approximately 240 per 100,000 [1].
Moderate-to-severe ulcerative colitis
Subcutaneous injection

Crohn's disease

Information

New molecular entity
Takeda
Takeda

Development and Regulatory status

Discontinued
Discontinued
Discontinued
May 20SHP647 will be culled from pipeline. Clinical trials will be discontinued in due course. European Commission demanded Takeda divest of this medicine when they took over Shire, in order to maintain competitive market. No purchasers for drug have been found, so it has been dropped by Takeda [5].

Category

A fully human IgG2 monoclonal antibody that targets mucosal addressin cell adhesion molecule (MADCAM1)
The incidence and prevalence of Crohn's disease is increasing worldwide, with a systematic review reporting the highest incidence in Australia (29.3 per 100,000 population), Canada (20.2 per 100,000 population) and northern Europe (10.6 per 100,000). The prevalence in the UK is about 10.6 per 100,000 population [1,2].
Crohn's disease
Subcutaneous injection